SPDR S&P 500 High Dvd

Invesco BulletShares Corporate Bond ETF Announces Net Asset Value

Invesco BulletShares 2028 USD Corporate Bond UCITS ETF GBP Hdg Dist Financial Data Released

Invesco Announces NAV for BulletShares 2026 USD Corporate Bond ETF as of December 4, 2025

Merck Raises $8 Billion Through Multiple Tranches of Notes

APA Corporation Sees Significant Increase in Call Option Volume

FDA Approves Merck's New Parasitic Drug for Cattle

FDA Senior Official Richard Pazdur's Retirement Sparks Industry Attention

EDF Plans to Sell Minority Stake in Edison to Support Green Investments

CVS Health Corporation Plans to Simplify Healthcare with AI

Invesco Increases Stake in Deere

Panagora Asset Management Inc. reduces holdings in Merck & Co., Inc. stock

Edison International Launches Over 500MW Renewable Energy New Projects

Invesco Announces Net Asset Value Per Share for S&P 500 Equal Weight Swap UCITS ETF Acc

Ford plans to launch Bronco to replace discontinued Focus

Ford China Responds to Complaints from Old Owners of Mondeo

Fitch Upgrades Ford Auto Securitization Trust II Note Ratings

Merck's stock rises 1.3% after Goldman Sachs upgrades target price

Wells Fargo Analyst Updates CVS Health Target Price and Rating

Ford CEO Meets with President Trump and Transportation Secretary Buttigieg

River Wealth Advisors LLC Increased Holdings in Merck

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

Invesco BulletShares 2027 USD Corporate Bond UCITS ETF GBP Hdg Dist announced its net asset value as of December 4, 2025. The NAV is 1,223,900.62 GBP, with a NAV per share of 5.407 GBP. The ETF has 226,352 shares in issue. This information is provided by RNS, the news service of the London Stock Exchange.

London Stock Exchange

Invesco

REG - IVZ II 2027USD GBP D - Net Asset Value(s)

Invesco BulletShares 2028 USD Corporate Bond UCITS ETF GBP Hdg Dist has a net asset value of 989,827.77 GBP, with 183,490 shares issued and a NAV per share of 5.394 GBP as of December 4, 2025. This information is provided by RNS, the news service of the London Stock Exchange.

REG - IVZ II 2028USD GBP D - Net Asset Value(s)

Invesco US Treasury Bond 10+ Year UCITS ETF GBP Hdg Dist announced its net asset value as of December 4, 2025. The fund's NAV is £17,857,726.20, with a NAV per share of £4.141. The fund has 4,312,738 shares in issue. This information is provided by RNS, the news service of the London Stock Exchange.

REG - IVZ II UST 10+ Year£ - Net Asset Value(s)

Invesco Ltd. (NYSE:IVZ) has received a consensus "Hold" rating from 17 analysts, with 11 rating it as hold, 5 as buy, and 1 as strong buy. The average 12-month price target is $23.63. Recent analyst actions include Goldman Sachs lowering its target to $25.50 and Barclays raising it to $25.00. Invesco's recent earnings beat expectations, reporting $0.61 EPS. The company announced a quarterly dividend of $0.21, yielding 3.3% annually.

Market Beat

Invesco Ltd. (NYSE:IVZ) Given Consensus Rating of "Hold" by Analysts

Invesco Euro Government Bond 7-10 Year UCITS ETF USD Hdg Acc reported a Net Asset Value (NAV) of 119,750.80 USD as of December 4, 2025, with 22,684 shares issued and a NAV per share of 5.279 USD. This information is provided by RNS, the news service of the London Stock Exchange.

REG - IVZ II EU GOV 7-10 $ - Net Asset Value(s)

Invesco S&P World Health Care ESG UCITS ETF reports a net asset value of $70,135,107.32 as of December 4, 2025, with 10,800,000 shares issued and a NAV per share of $6.494. The information is provided by RNS, the news service of the London Stock Exchange.

REG - IVZ II S&P Wld Hlth$ - Net Asset Value(s)

Invesco FTSE RAFI UK 100 UCITS ETF announced its Net Asset Value (NAV) as of December 4, 2025. The NAV is £13,185,678.81, with a NAV per share of £15.187. The ETF has 868,201 shares in issue, and the information is provided by RNS, the news service of the London Stock Exchange.

REG - IVZ III FTSE RAFI UK - Net Asset Value(s)

HALO

Health-care stocks fell sharply as traders shifted to rate-sensitive sectors. Halozyme secured a preliminary injunction against Merck & Co. in a patent dispute over Keytruda in Germany. The Trump administration's biomedical innovation goals face challenges within the FDA, amid infighting and staff turnover influenced by Robert F. Kennedy Jr.'s policy changes.

marketscreener

Merck

Halozyme Therap

Health Care Down Sharply on Rotation to Rate-Sensitive Sectors -- Health Care Roundup

INVESCO Ltd. shares rose 3.36% to $25.21, outperforming competitors in a mixed trading session. The stock hit a new 52-week high, surpassing its previous peak of $24.79. Trading volume reached 7.6 million, above the 50-day average of 5 million. Competitors Morgan Stanley, BlackRock, and Goldman Sachs showed varied performance.

Dow Jones

INVESCO Ltd. Stock Outperforms Competitors On Strong Trading Day

CVS Health Corp. stock rose 2.33% to $76.75, outperforming competitors in a mixed market session. The S&P 500 increased by 0.11%, while the Dow Jones fell by 0.07%. CVS snapped a three-day losing streak and closed 9.86% short of its 52-week high. Trading volume was 8.5M, above the 50-day average of 7.3M. Competitors like Amazon and UnitedHealth saw declines, while Elevance Health rose slightly.

CVS Health

CVS Health Corp. Stock Outperforms Competitors On Strong Trading Day

Merck & Co., Inc. has raised $8 billion through a multi-tranche notes offering, including various debt instruments with maturities ranging from 2029 to 2065. The offering closed on December 4, 2025, under the company's shelf registration statement filed with the SEC. This capital raising effort involves several series of notes with varying interest rates and maturities.

Reuters

Merck Raises $8 Billion in Multi-Tranche Notes Offering

AMGN

ABBV

Amgen Inc. shares fell 1.52% to $340.16 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Amgen's stock ended a two-day winning streak and closed 1.80% below its 52-week high. Competitors' performances varied: Johnson & Johnson fell 1.39%, Pfizer rose 0.51%, and AbbVie fell 0.66%. Trading volume was 3.4 million, above the 50-day average of 2.5 million.

Johnson & Johnson

Amgen

Abbvie

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

LaMonica Susan Officer of Citizens Financial Group Inc [CFG] filed a Form 4 on December 4, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/3/25TransactionGiftShares20,128Price$55.68Value$1,120,727Ending Holdings: 169,796 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Citizens Financial

Officer LaMonica Gifts 20,128 Of Citizens Financial Group Inc [CFG]

Scotiabank raised its target price for Merck & Co., Inc. (NYSE:MRK) from $105.00 to $120.00, giving the stock a "sector outperform" rating. This suggests a potential upside of 18.98% from the current price. Other analysts have mixed ratings, with some upgrading and others downgrading their ratings. Merck's recent earnings report showed a revenue increase of 3.7% year-over-year and an EPS of $2.58, beating estimates. The company has set its FY 2025 guidance at 8.930-8.980 EPS.

Scotiabank Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Citizens Financial Group (NYSE:CFG) hit a new 52-week high of $55.55. Analysts have mixed ratings: DA Davidson and UBS Group rate it a 'buy' with price targets of $59.00 and $62.00, respectively. Truist Financial rates it 'hold' with a $56.00 target. The company reported strong Q3 earnings and increased its dividend to $0.46 per share. Institutional investors have shown increased interest in CFG shares.

Citizens Financial Group (NYSE:CFG) Sets New 52-Week High  - Still a Buy?